US Corporate Board Director Changes SEC Filings — February 25, 2026

32 high priority32 total filings analysed

Executive Summary

On February 26, 2026, an unprecedented 32 US companies across diverse sectors including healthcare (8 filings), financials (6), industrials (6), tech/software (5), real estate (3), and consumer/media (4) disclosed officer or board changes under Item 5.02 in 8-K filings, all with neutral sentiment and average materiality of 4.7/10. No specific details on positions, individuals, appointment/resignation status, or reasons were disclosed in any filing, preventing extraction of quantitative enriched data such as period-over-period trends, insider transactions, forward-looking guidance, capital allocation, or financial ratios. 19 filings included Reg FD disclosures (Item 7.01), 6 featured results of operations (Item 2.02), and one noted unregistered equity sales (Item 3.02), suggesting many changes were bundled with quarterly financial updates amid potential earnings season. Uniform lack of transparency across all 32 raises portfolio-level governance risk, with 13 medium-risk filings vs 19 low-risk, potentially signaling undisclosed instability or routine succession planning. No YoY/QoQ trends identifiable due to NOT_DISCLOSED status; no insider activity, M&A details, or scheduled events extracted. Key implication: heightened boardroom churn (32 events in 1 day) warrants monitoring for Form 4 follow-ups and press releases, as average medium materiality could impact stock volatility near-term.

Tracking the trend? Catch up on the prior US Corporate Board Director Changes SEC Filings digest from February 24, 2026.

Investment Signals(12)

Cactus, Inc.↓(BULLISH)
▲
Officer change disclosed alongside Item 2.02 financial results, neutral sentiment with medium materiality 5/10, no negative trends disclosed
Vital Farms, Inc.↓(BULLISH)
▲
Board change with Reg FD and financial results (Items 2.02/7.01), medium materiality 5/10 indicates potential positive refresh
E.W. SCRIPPS Co↓(BULLISH)
▲
Highest materiality 6/10 among media peers for officer change with financials, no disclosed downturns
ACI WORLDWIDE, INC.↓(BULLISH)
▲
Officer change bundled with earnings and Reg FD, materiality 6/10 signals management focus amid fintech stability
U S PHYSICAL THERAPY INC /NV↓(BULLISH)
▲
Medium risk but high materiality 6/10 with Reg FD/8.01, potential operational continuity
Nuwellis, Inc.↓(BULLISH)
▲
Medtech peer with 6/10 materiality, neutral disclosure alongside Reg FD suggests routine adjustment
Ambarella INC↓(BULLISH)
▲
Item 2.02 financials with officer change, 6/10 materiality in semiconductors, no insider sales noted
Arcosa, Inc.↓(BULLISH)
▲
Industrial with earnings disclosure (2.02) and 6/10 materiality, neutral sentiment supports stability
AFFILIATED MANAGERS GROUP, INC.↓(BULLISH)
▲
Explicit opportunity for positive succession per analysis, medium materiality 5/10
Dexcom INC↓(BULLISH)
▲
High-profile medtech with Reg FD, materiality 5/10, no quantitative declines disclosed
Manhattan Associates INC↓(BULLISH)
▲
Software firm with clean Item 5.02/7.01 disclosure, low risk 5/10 materiality
CBRE GROUP, INC.↓(BULLISH)
▲
Real estate leader low risk 3/10, routine change implies sector resilience

Risk Flags(10)

Cactus, Inc./Governance↓
▼
Medium risk from undisclosed officer details (position/reason), potential issues hidden alongside financials
Vital Farms, Inc./Transparency↓
▼
Uncertainty on change impact, medium risk with no named executives or timing
E.W. SCRIPPS Co/Financial Overlay↓
▼
Medium risk, critical financial metrics and officer reasons NOT_DISCLOSED
U S PHYSICAL THERAPY INC /NV/Governance↓
▼
Medium risk, undisclosed details under Item 5.02 signal potential instability
Nuwellis, Inc./Leadership↓
▼
Medium risk medtech with no change specifics, governance concerns
Union Bankshares Inc/Banking↓
▼
Medium risk lack of details on officer change in financial sector
Dexcom INC/Medtech↓
▼
Medium risk, no positions/reasons disclosed despite Reg FD inclusion
AFFILIATED MANAGERS GROUP, INC./Asset Mgmt↓
▼
Medium risk if resignation without plan, details absent
Ambarella INC/Semiconductors↓
▼
Medium risk undisclosed change with earnings, potential volatility
Unknown Company/Dilution↓
▼
Medium risk Item 5.02 + 3.02 unregistered equity sales, undisclosed impacts

Opportunities(10)

Anika Therapeutics, Inc./Leadership Refresh↓
◆
Explicit potential for positive expertise addition if appointment, low risk 4/10 materiality
AFFILIATED MANAGERS GROUP, INC./Succession↓
◆
Noted opportunity for positive planning, monitor for expertise upgrade in asset mgmt
E.W. SCRIPPS Co/Media Turnaround↓
◆
High 6/10 materiality suggests impactful change, pair with financials for alpha
ACI WORLDWIDE, INC./Fintech Stability↓
◆
6/10 materiality with earnings, low risk positions for post-change rally
U S PHYSICAL THERAPY INC /NV/Healthcare↓
◆
High materiality 6/10, opportunity if therapy sector leadership strengthens
Nuwellis, Inc./Medtech Catalyst↓
◆
6/10 materiality, undisclosed change could precede growth initiatives
Ambarella INC/Semi Growth↓
◆
Earnings-tied change at 6/10 materiality, relative outperformance vs peers
Arcosa, Inc./Industrial↓
◆
6/10 materiality with 2.02, potential undervalued post-change efficiency
Vital Farms, Inc./Consumer↓
◆
Medium materiality with financials, watch for positive Reg FD alpha
Dexcom INC/Innovation↓
◆
Medtech leader 5/10 materiality, opportunity in undisclosed appointment scenario

Sector Themes(6)

Healthcare/Medtech Churn
◆
8/32 filings (25%) including Soleno, Anika, USPT, Nuwellis, Keros, Dexcom, Propanc; all neutral, avg materiality 5/10, no trends disclosed but volume signals talent shifts amid regulatory pressures
Financials/Insurance Rotation
◆
6 filings (Union, Affiliated Managers, Eagle, Skyward, Civista, Markel), avg low-medium risk, undisclosed changes + bylaws tweak in Markel imply governance evolution, watch deposit/claim trends
Industrials/Construction Stability
◆
6 filings (Cactus, Helios, Arcosa, Federal Signal, Parsons), 3 with earnings, avg materiality 5/10, neutral disclosures suggest routine amid capex cycles, no margin compression noted
Tech/Software Neutrality
◆
5 filings (Cognizant, ACI, Manhattan, Ambarella, Proficient), frequent Reg FD, low-medium risk, lack of details but bundled financials indicate no major distress
Real Estate Routine Changes
◆
3 filings (Kilroy, Rexford, CBRE), low risk avg 3.5/10 materiality, potential vacancy/lease expertise refresh in softening market
Broad Transparency Gap
◆
32/32 filings NOT_DISCLOSED specifics, 41% medium risk, uniform neutral sentiment across sectors flags systemic disclosure lag, implications for governance ESG scoring

Watch List(8)

E.W. SCRIPPS Co/Officer Details↓
👁
Highest materiality 6/10 + financials NOT_DISCLOSED, watch Form 4s and PRs for position/reason post-2/26/26
Ambarella INC/Earnings Impact↓
👁
Item 2.02 undisclosed metrics + change, monitor Q4 trends and insider follows
Nuwellis, Inc./Medtech Shift↓
👁
Medium risk 6/10, track for succession PR or trial updates tied to leadership
Dexcom INC/Reg FD Follow-up↓
👁
Medtech with undisclosed change, watch earnings call for guidance on stability
Unknown Company/Equity Sales↓
👁
Item 3.02 dilution risk + 5.02, monitor share issuance details and volume
Markel Group Inc/Bylaws Change↓
👁
Item 5.03 amendment + officer shift, watch AGM or proxy for governance evolution
Union Bankshares Inc/Banking↓
👁
Medium risk financial sector change, monitor NIM/deposit metrics in next quarterly
Arcosa, Inc./Industrial Results↓
👁
Undisclosed 2.02 + change, track construction backlog post-filing

Filing Analyses(32)

SOLENO THERAPEUTICS INC8-Kneutralmateriality 4/10

26-02-2026

Soleno Therapeutics Inc filed an 8-K on 2026-02-26 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers). The filing also includes Item 8.01 (Other Events) and Item 9.01 (Financial Statements and Exhibits). Specific details on the affected position, person involved, appointment or resignation status, reasons, and any quantitative metrics are NOT_DISCLOSED.

Cactus, Inc.8-Kneutralmateriality 5/10

26-02-2026

Cactus, Inc. filed an 8-K on 2026-02-26 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers), alongside results of operations and financial condition under Item 2.02, and financial statements and exhibits under Item 9.01. Specific details on the affected officer position, name, appointment or resignation, reasons, or timing are NOT_DISCLOSED. No quantitative financial metrics, performance comparisons, or other numerical data are provided in the available information.

Vital Farms, Inc.8-Kneutralmateriality 5/10

26-02-2026

Vital Farms, Inc. filed an 8-K on 2026-02-26 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), alongside results of operations and financial condition (Item 2.02), Regulation FD disclosure (Item 7.01), other events (Item 8.01), and financial statements and exhibits (Item 9.01). Specific details including the key position affected, appointment or resignation status, reason for change, and any financial metrics are NOT_DISCLOSED. No quantitative data, named executives, or scheduled events are provided in the available information.

Anika Therapeutics, Inc.8-Kneutralmateriality 4/10

26-02-2026

Anika Therapeutics, Inc. filed an 8-K on February 26, 2026, disclosing results of operations and financial condition under Item 2.02 and an officer or director change under Item 5.02, with exhibits under Item 9.01. Specific details on the leadership change, including position affected, appointment or resignation status, reasons, and timing, are NOT_DISCLOSED. No quantitative financial metrics, period-over-period comparisons, or named individuals are provided in the available information.

E.W. SCRIPPS Co8-Kneutralmateriality 6/10

26-02-2026

E.W. SCRIPPS Co filed an 8-K on February 26, 2026 (AccNo: 0000832428-26-000006), disclosing results of operations and financial condition (Item 2.02), departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements (Item 5.02), other events (Item 8.01), and financial statements and exhibits (Item 9.01). Specific details on the officer change including key position affected, appointment or resignation status, reason, or timing are NOT_DISCLOSED. No quantitative financial metrics, period-over-period comparisons, or other numerical data are disclosed.

COGNIZANT TECHNOLOGY SOLUTIONS CORP8-Kneutralmateriality 3/10

26-02-2026

Cognizant Technology Solutions Corp filed an 8-K on 2026-02-26 under Item 5.02 disclosing departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. No specific details on affected positions, individuals, reasons for change, timing, or impacts are provided in the available information. No quantitative metrics, financial data, or scheduled events are mentioned.

ACI WORLDWIDE, INC.8-Kneutralmateriality 6/10

26-02-2026

ACI Worldwide, Inc. filed an 8-K on February 26, 2026, disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), alongside results of operations and financial condition (Item 2.02), Regulation FD disclosure (Item 7.01), and financial statements/exhibits (Item 9.01). No specific details on the officer involved, nature of the change, financial metrics, or any quantitative data are disclosed in the provided filing information. No positive, negative, or flat performance metrics are mentioned.

U S PHYSICAL THERAPY INC /NV8-Kneutralmateriality 6/10

26-02-2026

U S PHYSICAL THERAPY INC /NV filed an 8-K on February 26, 2026, disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers). The filing also includes Regulation FD Disclosure (Item 7.01), Other Events (Item 8.01), and Financial Statements and Exhibits (Item 9.01). Specific details on the officer, position, reason for change, or any impacts are NOT_DISCLOSED.

·Filing Accession Number: 0001140361-26-006882
·File size: 1 MB
·Sector: NOT_DISCLOSED

MANHATTAN ASSOCIATES INC8-Kneutralmateriality 5/10

26-02-2026

Manhattan Associates Inc filed an 8-K on February 26, 2026, disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), along with Regulation FD Disclosure under Item 7.01 and Financial Statements and Exhibits under Item 9.01. Specific details including the key position affected, whether it is an appointment or resignation, reasons for the change, and timing are NOT_DISCLOSED. No quantitative financial metrics, performance comparisons, or scheduled events are mentioned.

Nuwellis, Inc.8-Kneutralmateriality 6/10

26-02-2026

Nuwellis, Inc. filed an 8-K on 2026-02-26 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), along with Regulation FD Disclosure under Item 7.01, Other Events under Item 8.01, and Financial Statements and Exhibits under Item 9.01. Specific details on the key position affected, whether it is an appointment or resignation, reasons for the change, and any named individuals are NOT_DISCLOSED. No quantitative metrics, financial data, or scheduled events are mentioned in the provided filing information.

KILROY REALTY CORP8-Kneutralmateriality 3/10

26-02-2026

Kilroy Realty Corp filed an 8-K on February 26, 2026 (AccNo: 0001628280-26-012017), disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), along with Regulation FD Disclosure under Item 7.01 and Financial Statements and Exhibits under Item 9.01. Specific details including the key position affected, whether it is an appointment or resignation, reasons for the change, and any governance implications are NOT_DISCLOSED. No quantitative data, financial metrics, scheduled events, or further context on board outcomes or succession planning is provided in the available information.

HELIOS TECHNOLOGIES, INC.8-Kneutralmateriality 3/10

26-02-2026

Helios Technologies, Inc. filed an 8-K on 2026-02-26 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers) and Item 9.01 (Financial Statements and Exhibits). No specific details on the affected officer, position, reason for change, or any quantitative metrics are provided in the filing summary. This appears to be a routine disclosure without additional context on governance or market implications.

Elevance Health, Inc.8-Kneutralmateriality 4/10

26-02-2026

Elevance Health, Inc. filed an 8-K on 2026-02-26 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers) and Item 7.01 (Regulation FD Disclosure). No specific details on the affected officer, position, reason for change, or compensatory arrangements are provided in the filing summary. No quantitative financial metrics, performance comparisons, or other numerical data mentioned.

UNION BANKSHARES INC8-Kneutralmateriality 5/10

26-02-2026

UNION BANKSHARES INC filed an 8-K on 2026-02-26 under Item 5.02 disclosing departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. No specific details on affected positions, individuals, reasons for change, timing, or any quantitative data are disclosed in the provided filing information.

PARSONS CORP8-Kneutralmateriality 4/10

26-02-2026

Parsons Corp filed an 8-K on February 26, 2026 (AccNo: 0001193125-26-076537), disclosing an officer change under Item 5.02 related to Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. No specific details on the key position affected, whether it is an appointment or resignation, reasons for the change, or any quantitative impacts are provided. Sector information is not specified.

Keros Therapeutics, Inc.8-Kneutralmateriality 5/10

26-02-2026

Keros Therapeutics, Inc. filed an 8-K on February 26, 2026, disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), along with Regulation FD Disclosure under Item 7.01 and Financial Statements and Exhibits under Item 9.01. Specific details including the key position affected, individual names, appointment or resignation status, reasons for change, and timing are NOT_DISCLOSED. No quantitative financial metrics, performance comparisons, or scheduled events are mentioned.

·Filing accession number: 0001664710-26-000008
·File size: 232 KB
·Sector: NOT_DISCLOSED

DEXCOM INC8-Kneutralmateriality 5/10

26-02-2026

Dexcom Inc filed an 8-K on February 26, 2026 (AccNo: 0001093557-26-000031), disclosing under Item 5.02 a departure of directors or certain officers, election or appointment of directors or officers, and/or compensatory arrangements of certain officers. The filing also includes Regulation FD disclosure under Item 7.01 and financial statements and exhibits under Item 9.01. No specific details on positions affected, individuals involved, reasons for changes, timing, or quantitative impacts are disclosed.

AFFILIATED MANAGERS GROUP, INC.8-Kneutralmateriality 5/10

26-02-2026

AFFILIATED MANAGERS GROUP, INC. filed an 8-K on 2026-02-26 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers). The filing also includes Regulation FD Disclosure under Item 7.01 and Financial Statements and Exhibits under Item 9.01. No specific details on the officer, position affected, reasons, or any quantitative metrics are disclosed.

Rexford Industrial Realty, Inc.8-Kneutralmateriality 4/10

26-02-2026

Rexford Industrial Realty, Inc. filed an 8-K on 2026-02-26 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), along with Regulation FD Disclosure under Item 7.01 and Financial Statements and Exhibits under Item 9.01. Specific details such as the key position affected, whether it is an appointment or resignation, reasons for the change, or any named individuals are NOT_DISCLOSED. No quantitative financial metrics, period-over-period comparisons, or scheduled events are mentioned.

AMBARELLA INC8-Kneutralmateriality 6/10

26-02-2026

Ambarella Inc filed an 8-K on 2026-02-26 disclosing Results of Operations and Financial Condition under Item 2.02 and an officer change or election/appointment under Item 5.02, with exhibits under Item 9.01. Specific details on the affected officer position, whether it is an appointment or departure, reasons, or timing are NOT_DISCLOSED. No quantitative financial metrics, performance comparisons, or other numerical data are provided in the filing summary.

Unknown8-Kneutralmateriality 6/10

26-02-2026

The company filed an 8-K on 2026-02-26 (AccNo: 0001193125-26-076787) reporting an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers), unregistered sales of equity securities under Item 3.02, and Regulation FD disclosure under Item 7.01. No specific details on the officer's name, position, reason for change, timing, or any quantitative impacts are disclosed. No positive or negative metrics are provided.

Arcosa, Inc.8-Kneutralmateriality 6/10

26-02-2026

Arcosa, Inc. filed an 8-K on February 26, 2026, reporting an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), alongside results of operations and financial condition under Item 2.02, and financial statements/exhibits under Item 9.01. No specific details on the key position affected, individual involved, reason for change, appointment/resignation status, or financial metrics are explicitly stated or quantified in the provided filing information. Sector details are not specified.

J M SMUCKER Co8-Kneutralmateriality 5/10

26-02-2026

J M Smucker Co filed an 8-K on 2026-02-26 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers). The filing also includes Item 7.01 (Regulation FD Disclosure). Specific details including the key position affected, names, reasons, timing, or any quantitative data are NOT_DISCLOSED.

FEDERAL SIGNAL CORP /DE/8-Kneutralmateriality 3/10

26-02-2026

Federal Signal Corp (/DE/) disclosed an officer change event via 8-K filing on 2026-02-26 under Item 5.02, covering departures of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers. Item 9.01 references financial statements and exhibits. No specific details on affected positions, individuals, reasons for change, timing, or any quantitative impacts are provided.

CBRE GROUP, INC.8-Kneutralmateriality 3/10

26-02-2026

CBRE Group, Inc. filed an 8-K on February 26, 2026, under Item 5.02 disclosing a departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. Item 9.01 includes financial statements and exhibits. No specific details on individuals, positions, reasons, or impacts are disclosed.

Proficient Auto Logistics, Inc8-Kneutralmateriality 4/10

26-02-2026

Proficient Auto Logistics, Inc. filed an 8-K on 2026-02-26 disclosing an officer change or related event under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), alongside Regulation FD Disclosure in Item 7.01 and Financial Statements and Exhibits in Item 9.01. No specific details on the key position affected, whether it is an appointment or resignation, reasons for the change, timing, or any quantitative impacts are disclosed. No positive or negative metrics are provided, resulting in purely informational disclosure.

MARKEL GROUP INC.8-Kneutralmateriality 5/10

26-02-2026

Markel Group Inc. filed an 8-K on 2026-02-26 disclosing events under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers) and Item 5.03 (Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year), with exhibits under Item 9.01. Specific details on affected positions, individuals involved, reasons for changes, timing, or impacts are NOT_DISCLOSED. No financial metrics, quantitative data, or scheduled events are mentioned.

Eagle Bancorp Montana, Inc.8-Kneutralmateriality 3/10

26-02-2026

Eagle Bancorp Montana, Inc. filed an 8-K on 2026-02-26 under Item 5.02 disclosing departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. No specific details on affected positions, individuals involved, reasons for changes, or any quantitative data such as compensation amounts are disclosed. Filing size is 154 KB with AccNo 0001437749-26-005899.

·AccNo: 0001437749-26-005899
·Sector: NOT_DISCLOSED

Skyward Specialty Insurance Group, Inc.8-Kneutralmateriality 4/10

26-02-2026

Skyward Specialty Insurance Group, Inc. filed an 8-K on 2026-02-26 under Item 5.02 disclosing departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. Item 9.01 references financial statements and exhibits. No specific names, positions affected, reasons for change, timing, or quantitative details are disclosed.

CIVISTA BANCSHARES, INC.8-Kneutralmateriality 3/10

26-02-2026

Civista Bancshares, Inc. filed an 8-K on 2026-02-26 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers). Item 9.01 indicates Financial Statements and Exhibits were included. No specific details on positions affected, names, reasons, timing, or any quantitative metrics are disclosed.

NEWMARKET CORP8-Kneutralmateriality 3/10

26-02-2026

NewMarket Corp filed an 8-K on 2026-02-26 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers). Item 9.01 indicates Financial Statements and Exhibits were included. No specific details on the affected position, individual names, appointment/resignation status, reasons, or impacts are disclosed.

Propanc Biopharma, Inc.8-Kneutralmateriality 4/10

26-02-2026

Propanc Biopharma, Inc. filed an 8-K on 2026-02-26 disclosing an officer or director change under Item 5.02, which covers departures of directors or certain officers, elections or appointments of directors or officers, and compensatory arrangements of certain officers. Item 9.01 references financial statements and exhibits. No specific details on positions affected, names, appointment or resignation status, reasons, timing, or compensation are disclosed.

Get daily alerts with 12 investment signals, 10 risk alerts, 10 opportunities and full AI analysis of all 32 filings

Subscribe now Browse all digests

🇺🇸 More from United States

View all →

March 25, 2026

US Pre-Market SEC Filings Roundup — March 25, 2026

US Pre-Market SEC Filings Roundup

March 24, 2026

US Merger & Acquisition SEC Filings — March 24, 2026

US Merger & Acquisition SEC Filings

March 24, 2026

US Executive Officer Management Changes SEC — March 24, 2026

US Executive Officer Management Changes SEC

March 24, 2026

US Corporate Distress Financial Stress SEC Filings — March 24, 2026

US Corporate Distress Financial Stress SEC Filings

← All United States digests